MREO Stock Price and Chart — NASDAQ:MREO — TradingView

About Mereo BioPharma Group plc

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Check out other big names from the same industry as MREO.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Technicals

Summarizing what the indicators are suggesting.

Neutral

SellBuy

Strong sellStrong buy